Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers

Clinical Pharmacokinetics

Volumn 40, Issue SUPPL. 1, 2001, Pages 27-32

  Stass, Heino ^a   Wandel, Christoph ^a   Delesen, Heinz ^a   Möller, Jan Georg ^a  

^a BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM GLUBIONATE; MOXIFLOXACIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CALCIUM INTAKE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG TOLERABILITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; AREA UNDER THE MOMENT CURVE; CAUCASIAN; DRUG HALF LIFE; DRUG SAFETY; ELIMINATION RATE CONSTANT; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MORNING DOSAGE; ORAL CLEARANCE; PHARYNGITIS; PLASMA CONCENTRATION-TIME CURVE; RENAL CLEARANCE; RHINITIS; SINGLE DRUG DOSE; SUPPLEMENTATION; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUME OF DISTRIBUTION;

EID: 0035071377     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200140001-00004     Document Type: Article

References (2)

1. Dalhoff A, Petersen U, Endermann R. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy 1996; 42:410-25
2. Rouse MS, Piper KE, Patel R, et al. In vitro and in vivo activity of BAY 12-8039 or trovafloxacin against penicillin-resistant Streptococcus pneumoniae experimental pneumonia in immunocompetent mice [abstract no. B45]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15-18; New Orleans, Louisiana: 29